These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9636630)

  • 1. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction.
    Burke GW; Ciancio G; Alejandro R; Roth D; Ricordi C; Tzakis A; Miller J
    Transplant Proc; 1998 Jun; 30(4):1544-5. PubMed ID: 9636627
    [No Abstract]   [Full Text] [Related]  

  • 3. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
    Woodle ES; Bluestone JA; Zivin RA; Jolliffe LK; Auger J; Xu D; Thistlethwaite JR
    Transplant Proc; 1998 Jun; 30(4):1369-70. PubMed ID: 9636555
    [No Abstract]   [Full Text] [Related]  

  • 4. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy.
    Millis JM; Cronin DC; Newell KA; Piper JB; Woodle ES; Bruce DS; Conjeevaram H; Baker AL; Thistlethwaite JR
    Transplant Proc; 1997; 29(1-2):1549. PubMed ID: 9123421
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus in late acute OKT3-resistant and/or steroid-resistant rejection after simultaneous pancreas and kidney transplantation.
    Kahl A; Oppert M; Müller A; Settmacher U; Lepenies J; Klupp J; Kampf D; Neuhaus P; Frei U
    Transplant Proc; 2002 Sep; 34(6):2253-5. PubMed ID: 12270387
    [No Abstract]   [Full Text] [Related]  

  • 6. Pancreas after kidney transplantation: HLA mismatch does not preclude success.
    Basadonna GP; Auersvald LA; Oliveira SC; Friedman AL; Lorber MI
    Transplant Proc; 1997; 29(1-2):667. PubMed ID: 9123470
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

  • 8. One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis.
    Güz G; Emiroğlu R; Demirhan B; Köseoğlu F; Karakayali H; Bilgin N
    Transplant Proc; 2000 May; 32(3):572-3. PubMed ID: 10812117
    [No Abstract]   [Full Text] [Related]  

  • 9. Pancreas transplantation with ATG vs OKT3.
    Rosenberg L
    Transplant Proc; 1997 Nov; 29(7A):35S-36S. PubMed ID: 9366927
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term renal and pancreas function with tacrolimus rescue therapy following kidney/pancreas transplantation.
    Hariharan S; Peddi VR; Munda R; Demmy AM; Schroeder TJ; Alexander JW; First MR
    Transplant Proc; 1997; 29(1-2):652-3. PubMed ID: 9123462
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 12. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
    Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of OKT3 induction therapy in cadaveric kidney transplantation.
    Alsina J; Bover J; Grinyó JM
    Am J Kidney Dis; 1996 Dec; 28(6):958. PubMed ID: 8957053
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection in simultaneous kidney and pancreas transplant recipients.
    Peddi VR; Kamath S; Schroeder TJ; Munda R; First MR
    Transplant Proc; 1998 Mar; 30(2):285-7. PubMed ID: 9532041
    [No Abstract]   [Full Text] [Related]  

  • 15. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS; Newell KA; Woodle ES; Millis JM; Piper JB; Huss E; Thistlethwaite JR
    Transplant Proc; 1996 Aug; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody induction therapy in pancreas transplantation.
    Gruessner RW
    Transplant Proc; 1998 Jun; 30(4):1556-9. PubMed ID: 9636632
    [No Abstract]   [Full Text] [Related]  

  • 17. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation.
    Shield CF; Jacobs RJ; Wyant S; Das A
    Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term prednisolone withdrawal after pancreas and kidney transplantation in patients treated with ATG, tacrolimus, and mycophenolate mofetil.
    Kahl A; Bechstein WO; Lorenz F; Steinberg J; Pohle C; Kampf D; Müller A; Settmacher U; Neuhaus P; Frei U
    Transplant Proc; 2001; 33(1-2):1694-5. PubMed ID: 11267473
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy.
    Kaufman DB; Leventhal JR; Stuart J; Parker M; Abecassis M; Fryer JP; Stuart FP
    Transplant Proc; 1999; 31(1-2):615-6. PubMed ID: 10083261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.